CBL-B Inhibitor-treated Autologous Tumor-infiltrating Lymphocytes DeTIL-0255

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous tumor-infiltrating lymphocytes (TILs) derived from a patient's tumor that have been treated ex vivo during cell expansion with NX-0255, an inhibitor of Casitas B-lineage lymphoma proto-oncogene-b (CBL-B), with potential immunomodulating and antineoplastic activities. Upon administration, the CBL-B inhibitor-treated autologous TILs DeTIL-0255 specifically recognize and kill the patient's tumor cells. NX-0255 enhances TIL expansion and the tumor-killing ability of the TILs when returned to the patient.

**Synonyms:** - Autologus TILs DeTIL-0255 - DeTIL NX-0255 - DeTIL NX0255 - DeTIL-0255 - NX-0255 Drug-enhanced TILs - NX-0255-treated Autologous TILs DeTIL-0255